Barbara Botto is an academic researcher from the University of Turin. She is rated as a distinguished expert by MediFind in the treatment of Hodgkin lymphoma. She has authored over 65 publications with 2494 total citations and an H-index of 26 (Scopus). Her top areas of expertise are primary mediastinal B-cell lymphoma (PMBCL), Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell lymphoma, and bone marrow transplant.
Federica Cavallo is a Full Professor of immunology at the
University of Torino. After graduating in Biological Sciences from Turin
University in July 1989, she was selected for the Ph.D. program in 1991
(immunology) at the University of Turin. In 1995, she obtained a postdoctoral
fellowship at the Italian Ministry of Health to work on AIDS research, while in
1996, she was selected for a postdoctoral fellowship at the University of Turin to
study the ability of rIL-12 to activate anti-angiogenic activity in tumor
cells. In the same year, she was the recipient of the Award on Innovative
Therapies, Italian Society for Cancer Research, Milan, Italy. From 1998 to 2000,
she was a researcher at the Center of Immunogenetics and Experimental Oncology
CIOS, National Research Council, Turin, Italy, working on “Novel compounds that
inhibit the activation of CD4-positive T-cells as immunosuppressive agents”.
She was a tenured researcher at the University of Turin from 2001 to 2006 and
an Associate Professor from 2006 to 2016. She was the recipient of the Award on
Innovative Therapies, Italian Society for Cancer Research, Milan, Italy, in
1996; the Begnudelli Award, Pezcoller Foundation, Trento, Italy; and the
Angelo Costa Award, Medical School, University of Turin in 2005. In May 2016,
she won the “Made in Research” business game organized by the University of
Turin with the project “MeraVax”, a DNA vaccine for dogs with surgically
resected oral malignant melanoma.
Dr. Alessandro Busca is a Medical Doctor at the Stem Cell Transplant Center, AOU Città della Salute e della Scienza di Torino. He is a Specialist in hematology and pediatrics. His fields of interest are bone marrow transplantation from unrelated donors; haploidentical transplantation; antifungal drugs; fungal infections in stem cell transplant recipients and immunocompromised host; and bacterial and viral infections in stem cell transplant recipients and immunocompromised hosts.
Benedetto Bruno is an Associate Professor of hematology at the
Department of Molecular Biotechnology and Health Sciences, School of
Medicine, University of Turin, Italy, and Program Head of the Bone
Marrow Transplantation Unit at the A.O.U. Città della Salute e della
Scienza di Torino, Presidio Molinette, Turin, Italy. Following medical
training at the University of Pavia, Italy, he worked as a resident in
hematology at the University of Turin before taking up, in 1995, a
fellowship at the Department of Transplantation Biology at the Fred
Hutchinson Cancer Research Center, Seattle, WA, USA. He passed the
United States Medical License Examination in 1996, then returned to
Italy in 2000, when he received a doctorate in experimental hematology
from the University of Genoa. With a particular interest in the role of
autologous and allogeneic stem cell transplantation and cell therapies
in the treatment of hematological disorders, he has received several
awards, including the International Cancer Technology Transfer Award
from the International Union Against Cancer, Geneva, Switzerland, and
his research is published in a large number of high-impact peer-reviewed
journals.
Roberto Freilone received his degree (with
honors) in medicine and surgery, from the University of Turin and was licensed
to practice in 1992. In 1996, he won a two-year fellowship from the Piedmont
Regional Committee “Gigi Ghirotti” for a two-year research project in the field
of malignant hemopathies. He has collaborated as a contact person for
hematology in the following national and international research groups on
malignant hemopathies: IIL (Italian National Lymphoma Intergroup),
Multiregional Group for the Study of Lymphoproliferative Diseases GIMURELL, Piedmont
Group for the Study of Myelodysplastic Syndromes, and ILSG (International
Lymphoma Study Group). He is the Complex Structure Director and Medical Director
of Hematology at the A.O.U. Citta della Salute e della Scienza di Torino. He
has decades of experience in the management of malignant hemopathies. He is
the author of numerous national and international scientific publications and
scientific communications at national and international congresses. He has
been a speaker at national and international congresses. He is the principal
investigator of several prospective phase II-III experimental clinical trials.
